Affinity DataKi: 0.700nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from pregnant ratsMore data for this Ligand-Target Pair
Affinity DataKi: 1.30nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from near-term pregnant rhesus m...More data for this Ligand-Target Pair
Affinity DataKi: 1.30nMAssay Description:Ability to inhibit AVP stimulation of adenylate cyclase activity in the rat kidney medulla (AVP-V2) receptorMore data for this Ligand-Target Pair
Affinity DataKi: 1.30nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
Affinity DataKi: 3.40nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from pregnant ratsMore data for this Ligand-Target Pair
Affinity DataKi: 4.5nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
Affinity DataKi: 4.70nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from near-term pregnant rhesus m...More data for this Ligand-Target Pair
Affinity DataKi: 5.10nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from pregnant ratsMore data for this Ligand-Target Pair
Affinity DataKi: 5.10nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
Affinity DataKi: 6nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from pregnant ratsMore data for this Ligand-Target Pair
Affinity DataKi: 6nMAssay Description:Inhibition of [3H]arginine vasopressin binding to AVP-V2 site in rat kidney medulla.More data for this Ligand-Target Pair
Affinity DataKi: 7.30nMAssay Description:Binding affinity towards rat uterine receptor was determined using [3H]oxytocin as radioligandMore data for this Ligand-Target Pair
Affinity DataKi: 9.40nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
Affinity DataKi: 17nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from near-term pregnant rhesus m...More data for this Ligand-Target Pair
Affinity DataKi: 21nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
Affinity DataKi: 33nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from near-term pregnant rhesus m...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 58nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 60nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 70nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 80nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 101nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 102nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 103nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 110nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 110nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 138nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 160nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 169nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 170nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 180nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 180nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 180nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 200nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 240nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 280nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 280nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 280nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 280nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 280nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 310nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 320nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 320nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 350nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
Affinity DataKi: 370nMAssay Description:Compound was evaluated for OT receptor affinity by displacement of [3H]OT from binding sites in uterine tissue taken from nonlabor pregnant womenMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 400nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 430nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 440nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 480nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 500nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 520nMAssay Description:In vitro inhibitory activity against Urokinase-type plasminogen activator (microPa)More data for this Ligand-Target Pair